Abstract: For later non-small-cell lung cancer, surgery and chemotherapy are thought of much limitation, molecular target therapy of epidermal growth factor receptor is a very good choice. But, endothelial growth factor receptor tyrosine kinase inhibitors such as gefitinib and erotinib have been found some deficiency. As for its use, the patients, who have epidermal growth factor receptor mutation and oher clinical character, will benefit most. Moreover, patients will have resistance. So some substitute of them is necessary. It is positive that irreversible inhibitors of epidermal growth factor receptor tyrosine kinase, antibody of vascular endothelial growth factor receptor and antitumor vaccines are produced. While radionuclinde labbled epidermal growth factor have been used some malignancy with the expression of epidermal growth factor receptor, especial breast cancer. And coexpression of reporter gene and therapy gene in the same carrier, then are shift to the harmful cardiac cells and accept PET imaging, by which we can treat patients and observe the effect synchronously. Both are sure to be very attractive for later non-small-cell lung cancer, of course other malligancy included.